How to use antistreptolysin O titre.
Sen ES, Ramanan AV.
Arch Dis Child Educ Pract Ed. 2014 Dec;99(6):231-8. doi: 10.1136/archdischild-2013-304884. Epub 2014 Jan 30.
Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection.
Aikawa C, Kawashima K, Fukuzaki C, Nakakido M, Murase K, Nozawa T, Tsumoto K, Nakagawa I.
Biochem Biophys Res Commun. 2021 Aug 20;566:177-183. doi: 10.1016/j.bbrc.2021.06.021. Epub 2021 Jun 12.
Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques.
McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ.
Infect Immun. 1998 Aug;66(8):3705-10. doi: 10.1128/IAI.66.8.3705-3710.1998.
An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome.
Matsumura T, Nishiyama A, Aiko M, Ainai A, Ikebe T, Chiba J, Ato M, Takahashi Y.
BMC Res Notes. 2020 Sep 5;13(1):419. doi: 10.1186/s13104-020-05264-2.
A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children.
Frenck RW Jr, Laudat F, Liang J, Giordano-Schmidt D, Jansen KU, Gruber W, Anderson AS, Scully IL.
Pediatr Infect Dis J. 2023 Dec 1;42(12):1045-1050. doi: 10.1097/INF.0000000000004111. Epub 2023 Sep 22.
Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence.
Chiarot E, Faralla C, Chiappini N, Tuscano G, Falugi F, Gambellini G, Taddei A, Capo S, Cartocci E, Veggi D, Corrado A, Mangiavacchi S, Tavarini S, Scarselli M, Janulczyk R, Grandi G, Margarit I, Bensi G.
mBio. 2013 Jan 8;4(1):e00387-12. doi: 10.1128/mBio.00387-12.
Antistreptolysin O; a study of this antibody in health and in hemolytic streptococcus respiratory disease in man.
RANTZ LA, RANDALL E, RANTZ HH.
Am J Med. 1948 Jul;5(1):3-23. doi: 10.1016/0002-9343(48)90003-5.
Complement resistance mechanisms of streptococci.
Jarva H, Jokiranta TS, Würzner R, Meri S.
Mol Immunol. 2003 Sep;40(2-4):95-107. doi: 10.1016/s0161-5890(03)00108-1.
Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.
Herrera AL, Van Hove C, Hanson M, Dale JB, Tweten RK, Huber VC, Diel D, Chaussee MS.
PLoS One. 2020 Jun 23;15(6):e0235139. doi: 10.1371/journal.pone.0235139. eCollection 2020.
Deciphering salivary microbiome signature in Crohn's disease patients with different factors contributing to dysbiosis.
Elzayat H, Malik T, Al-Awadhi H, Taha M, Elghazali G, Al-Marzooq F.
Sci Rep. 2023 Nov 6;13(1):19198. doi: 10.1038/s41598-023-46714-8.
